Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial

Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in participants aged 3-17 years. A randomized, double-blind, placebo-controlled, phase 1/2 clinical trial wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Shengli, Duan, Kai, Zhang, Yuntao, Zeng, Xiaoqing, Zhao, Dongyang, Zhang, Huajun, Xie, Zhiqiang, Li, Xinguo, Peng, Cheng, Zhang, Wei, Yang, Yunkai, Chen, Wei, Gao, Xiaoxiao, You, Wangyang, Wang, Xuewei, Wang, Zejun, Shi, Zhengli, Wang, Yanxia, Yang, Xuqin, Li, Qingliang, Huang, Lili, Wang, Qian, Lu, Jia, Yang, Yongli, Guo, Jing, Zhou, Wei, Wan, Xin, Wu, Cong, Wang, Wenhui, Huang, Shihe, Du, Jianhui, Nian, Xuanxuan, Deng, Tao, Yuan, Zhiming, Shen, Shuo, Guo, Wanshen, Liu, Jia, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265248/
https://www.ncbi.nlm.nih.gov/pubmed/35812412
http://dx.doi.org/10.3389/fimmu.2022.898151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265248/
https://www.ncbi.nlm.nih.gov/pubmed/35812412
http://dx.doi.org/10.3389/fimmu.2022.898151

Ejemplares similares